

MYD88, L265P, Somatic Gene Mutation, DNA
Allele-Specific PCR, Varies

Patient ID SA00091631	Patient Name TESTINGRNV, REPORT	Birth Date 1999-11-11	Gender M	Age 17
Order Number SA00091631	Client Order Number SA00091631	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 02 Jun 2017 06:00		

MYD88 L265P Gene Mutation Analysis

Specimen Type

Peripheral blood

MCR

Final Diagnosis

Peripheral blood, MYD88 L265P Mutation Analysis,
Allele-specific PCR:

1 MCR

Negative for MYD88 L265P alteration.

Comment: The MYD88 L265P abnormality is highly associated (>90%) with the pathologic diagnosis of lymphoplasmacytic lymphoma and the clinical syndrome of Waldenstrom macroglobulinemia (LPL/WM), particularly in the setting of an elevated IgM serum monoclonal paraprotein. The MYD88 L265P mutation is also identified in some diffuse large B-cell lymphomas (DLBCL), with a higher prevalence observed in "immune privileged" sites (e.g. central nervous system, testis, breast, skin). A negative molecular result makes the specific diagnosis of LPL/

WM less likely; however, these results do not necessarily exclude the possibility of lymphoma in this specimen. Clinical, laboratory and pathologic correlation is required for final diagnosis and interpretation of these results. The analytical sensitivity of this assay is approximately 1% mutation detection in a wild type background.

Signing Pathologist: Melissa Tricker-Klar

ADDITIONAL INFORMATION

DNA was extracted from the specimen and subjected to allele-specific polymerase chain reaction (PCR) using an allele specific forward primer that distinguishes the presence of the MYD88 L265P mutation. The reaction also contains a wild-type forward 5' of the mutation site and a single reverse primer. Expected fragment lengths of PCR products are interpreted using capillary electrophoresis.

Received: 02 Jun 2017 15:25

Reported: 02 Jun 2017 15:55

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292